InGel was founded by Patrick Jiang, Pierre Colombe Dromel, Deepti Singh in 2022.

Who are InGel's investors?

InGel's investors include MassVentures, Service Provider Capital, The Venture Collective, ZAKA VC.

How much funding has InGel raised?

InGel has disclosed $350K raised across 1 round.

Where is InGel headquartered?

InGel is headquartered in Cambridge, US.

InGel

Cambridge, US · Founded 2022 · 4 known investors

Find your way into InGel

Each arrow is one introduction. Sign up to fill in the first one.

314 people can intro you to Deepti

Ask Jessica Sagers to introduce you to Deepti Singh

You →Jessica · together at Mass. Eye and Ear →Deepti

Your email: who you already know at InGel, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the InGel team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.

Biotech Deep Tech Healthtech

Founders & leadership

InGel was founded in 2022 by Patrick Jiang, Pierre Colombe Dromel, and Deepti Singh.

Patrick JiangCEO & Co-founderCEO & Co-founder at InGel Website

Pierre Colombe DromelChief Technology Officer & Co-founderChief Technology Officer & Co-founder at InGel Website

Deepti Singh Chief Scientific Officer & Co-founderDeepti Singh holds a Ph.D. in biomaterials-based tissue regeneration and trained at Yale and Harvard University. She is Co-founder and Chief Scientific Officer of InGel Therapeutics, which develops engineered cell therapies for retinal degenerative diseases using biomimetic hydrogel delivery systems.

Myron SpectorNamed on SEC filing

Michael YoungNamed on SEC filing

Investors · 4

MassVentureslisted by MassVenturesWaltham · $250K – $500K

Service Provider Capitallisted by Service Provider CapitalVail

How we know: the VCSheet dataset · Not right? Tell us

The Venture Collectivelisted by The Venture CollectiveMiami Beach · $100K – $500K

How we know: The Venture Collective's portfolio page · the VCSheet dataset · Not right? Tell us

ZAKA VClisted by ZAKA VCSan Francisco

How we know: ZAKA VC's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$350K disclosed across 1 round · 2022

▶$350KraisedAug 2022 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Myron SpectorDirector
Pierre Colombe DromelExecutive Officer, Director
Deepti SinghDirector
Michael YoungDirector

Offering amount: $1M
Amount sold: $350K
First sale: Jul 2022
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does InGel do?: InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.
Who founded InGel?: InGel was founded by Patrick Jiang, Pierre Colombe Dromel, Deepti Singh in 2022.
Who are InGel's investors?: InGel's investors include MassVentures, Service Provider Capital, The Venture Collective, ZAKA VC.
How much funding has InGel raised?: InGel has disclosed $350K raised across 1 round.
Where is InGel headquartered?: InGel is headquartered in Cambridge, US.